

Technology Advisory Committee D Interests Register

Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs [ID1399]

Publication Date: 13/07/2022

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Professor David Meads	Committee member	Indirect financial	Professor Meads is employed by the University of Leeds which has received funding from AbbVie and Janssen for research in an unrelated area.	N/A	16.06.2022	N/A	It was agreed that this declaration would not prevent Professor Meads from participating in discussions on this appraisal.
Helen McAteer	Patient expert	Indirect financial	Ms McAteer is the Chief Executive of the Psoriasis Association which has received funding from AbbVie, Almiral, Amgen, Eli Lilly, Janssen and UCB in the past twelve months.	N/A	07.12.2021	N/A	It was agreed that her declaration would not prevent Ms McAteer from providing expert advice to committee.